Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from ex

Annexon Eyes ‘Win Season’ With Q4 Vision Trial Data, GBS Filings Ahead

Annexon (NASDAQ:ANNX) executives used a Goldman Sachs Healthcare Conference session to outline the company’s upcoming clinical and regulatory catalysts, led by pivotal Phase III data expected in the fourth quarter for vonaprument in geographic atrophy, a form of advanced dry age-related macular dege

MarketBeat · Jun 9

CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms

CorMedix (NASDAQ:CRMD) CEO Joe said the company is preparing for several potential commercial and regulatory catalysts across its infectious disease and dialysis-related portfolio, including a possible expansion of REZZAYO into fungal infection prophylaxis and continued work to sustain DefenCath uti

MarketBeat · May 22

Classic Edinburgh Lothian bus pops up for sale - on the other side of the world

The stunning vintage bus is reportedly the last of its type to exist in the world - that you can still drive but it's 10,000 miles away.

Edinburgh Live · Mar 10, 2023

From analysis to the latest developments in health,
read the most diverse news in one place.

Analysts Expect Clarity Imminent On Intercept's NASH Story

RBC Capital Markets writes that following the Advanz deal, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) should be well-capitalized into make-or-break upcoming readouts for obeticholic acid (OCA) in NASH, with REGENERATE re-analyses on deck, REVERSE reading in the next quarter. The analysts say it remains challenging to get visibility on how the efficacy/safety analyses will look,…

Benzinga · May 9, 2022

Coverage From

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.